Chronic hepatitis C virus(HCV)infection is a major global public health problem,particularly in developing part of the world.Significant advances have been made in the early diagnosis and treatment of the disease.Its ...Chronic hepatitis C virus(HCV)infection is a major global public health problem,particularly in developing part of the world.Significant advances have been made in the early diagnosis and treatment of the disease.Its management has been particularly revolutionized during the past two decades.In this review,we summarize the major advances in the diagnostic and management armamentarium for chronic HCV infection.The focus of the present review is on the newer directly acting anti-viral agents,which have revolutionized the management of chronic HCV infection.Management of uncomplicated chronic HCV infection and of specific complications and special at-risk populations of patients will be covered in detail.Despite the advent and approval of highly effective and well tolerable oral agents,still many challenges remain,particularly the affordability,the equitable distribution and access to later drugs.The World Health Organization aims to eliminate viral hepatitis including HCV by 2030 since its poses a major public health threat.There is an urgent need to ensure uniform and early access to diagnostic and therapeutic facilities throughout the world if the later goal has to be realized.展开更多
The novel coronavirus disease 2019(COVID-19)pandemic,caused by severe acute respiratory syndrome coronavirus 2,has become a global challenge of unprecedented nature since December 2019.Although most patients with COVI...The novel coronavirus disease 2019(COVID-19)pandemic,caused by severe acute respiratory syndrome coronavirus 2,has become a global challenge of unprecedented nature since December 2019.Although most patients with COVID-19 exhibit mild clinical manifestations and upper respiratory tract involvement,in approximately 5%-10%of patients,the disease is severe and involves multiple organs,leading to multi-organ dysfunction and failure.The liver and gastrointestinal tract are also frequently involved in COVID-19.In the context of liver involvement in patients with COVID-19,many key aspects need to be addressed in both native and transplanted organs.This review focuses on the clinical presentations and laboratory abnormalities of liver function tests in patients with COVID-19 with no prior liver disease,patients with pre-existing liver diseases and liver transplant recipients.A brief overview of the history of COVID-19 and etiopathogenesis of the liver injury will also be described as a prelude to better understanding the above aspects.展开更多
文摘Chronic hepatitis C virus(HCV)infection is a major global public health problem,particularly in developing part of the world.Significant advances have been made in the early diagnosis and treatment of the disease.Its management has been particularly revolutionized during the past two decades.In this review,we summarize the major advances in the diagnostic and management armamentarium for chronic HCV infection.The focus of the present review is on the newer directly acting anti-viral agents,which have revolutionized the management of chronic HCV infection.Management of uncomplicated chronic HCV infection and of specific complications and special at-risk populations of patients will be covered in detail.Despite the advent and approval of highly effective and well tolerable oral agents,still many challenges remain,particularly the affordability,the equitable distribution and access to later drugs.The World Health Organization aims to eliminate viral hepatitis including HCV by 2030 since its poses a major public health threat.There is an urgent need to ensure uniform and early access to diagnostic and therapeutic facilities throughout the world if the later goal has to be realized.
文摘The novel coronavirus disease 2019(COVID-19)pandemic,caused by severe acute respiratory syndrome coronavirus 2,has become a global challenge of unprecedented nature since December 2019.Although most patients with COVID-19 exhibit mild clinical manifestations and upper respiratory tract involvement,in approximately 5%-10%of patients,the disease is severe and involves multiple organs,leading to multi-organ dysfunction and failure.The liver and gastrointestinal tract are also frequently involved in COVID-19.In the context of liver involvement in patients with COVID-19,many key aspects need to be addressed in both native and transplanted organs.This review focuses on the clinical presentations and laboratory abnormalities of liver function tests in patients with COVID-19 with no prior liver disease,patients with pre-existing liver diseases and liver transplant recipients.A brief overview of the history of COVID-19 and etiopathogenesis of the liver injury will also be described as a prelude to better understanding the above aspects.
